B. Riley Securities maintains Neuronetics at Buy, raises price target to $6 from $5

B. Riley Securities reaffirmed its Buy rating for Neuronetics and increased its price target to $6 from $5, suggesting a 146.9% upside from the Nov 5 close of $2.43, according to the firm.

Original reporting
Published Nov 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
B. Riley Securities maintains Neuronetics at Buy, raises price target to $6 from $5 — source image
Decision brief

The 30-second read

$STIMBullishMed
01

Why it matters

The price‑target increase suggests a short‑term upside opportunity.

02

Market read

Analyst target raise provides a fresh catalyst for a micro‑cap stock.

03

What to watch

Potential regulatory delays or competitive pressures not addressed in the note.

Relevance 5/10Novelty 5/10Timing: today

Background

Neuronetics (STIM) is a small‑cap neurotechnology company; analyst coverage is sparse.

Company-level read

Ticker impact

$STIMBullishHigh confidence
Context

B. Riley raised Neuronetics' price target to $6, indicating a bullish analyst view.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

Target increase signals improved outlook, likely prompting short-term buying.

Market effects

May lift sentiment in the neurotechnology/medical device sector.

Limited to US small‑cap investors.

Low, confined to Neuronetics and its niche peers.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • B. Riley Securities

    Equity research firm issuing the rating upgrade.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.